Cargando…

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.

The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, S. A., Morris, T. M., Parsons, S. L., Steele, R. J., Brown, P. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074768/
https://www.ncbi.nlm.nih.gov/pubmed/8912529
_version_ 1782138038961307648
author Watson, S. A.
Morris, T. M.
Parsons, S. L.
Steele, R. J.
Brown, P. D.
author_facet Watson, S. A.
Morris, T. M.
Parsons, S. L.
Steele, R. J.
Brown, P. D.
author_sort Watson, S. A.
collection PubMed
description The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P < 0.002) but not day 10. Formation of solid peritoneal deposits was significantly reduced to 77% of vehicle control when batimastat was administered from day 0 (P < 0.01) and 69% of control when administered from day 10 (P < 0.05). Thus, batimastat has the ability to reduce the volume of ascites forming in SCID mice injected intraperitoneally with the human colorectal cell line, C170HM2, when administered from day 0 but not from day 10. Solid peritoneal tumour deposits were significantly reduced in both treatment groups, highlighting the therapeutic potential of batimastat in this clinical condition. IMAGES:
format Text
id pubmed-2074768
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20747682009-09-10 Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Watson, S. A. Morris, T. M. Parsons, S. L. Steele, R. J. Brown, P. D. Br J Cancer Research Article The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P < 0.002) but not day 10. Formation of solid peritoneal deposits was significantly reduced to 77% of vehicle control when batimastat was administered from day 0 (P < 0.01) and 69% of control when administered from day 10 (P < 0.05). Thus, batimastat has the ability to reduce the volume of ascites forming in SCID mice injected intraperitoneally with the human colorectal cell line, C170HM2, when administered from day 0 but not from day 10. Solid peritoneal tumour deposits were significantly reduced in both treatment groups, highlighting the therapeutic potential of batimastat in this clinical condition. IMAGES: Nature Publishing Group 1996-11 /pmc/articles/PMC2074768/ /pubmed/8912529 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Watson, S. A.
Morris, T. M.
Parsons, S. L.
Steele, R. J.
Brown, P. D.
Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
title Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
title_full Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
title_fullStr Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
title_full_unstemmed Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
title_short Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
title_sort therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074768/
https://www.ncbi.nlm.nih.gov/pubmed/8912529
work_keys_str_mv AT watsonsa therapeuticeffectofthematrixmetalloproteinaseinhibitorbatimastatinahumancolorectalcancerascitesmodel
AT morristm therapeuticeffectofthematrixmetalloproteinaseinhibitorbatimastatinahumancolorectalcancerascitesmodel
AT parsonssl therapeuticeffectofthematrixmetalloproteinaseinhibitorbatimastatinahumancolorectalcancerascitesmodel
AT steelerj therapeuticeffectofthematrixmetalloproteinaseinhibitorbatimastatinahumancolorectalcancerascitesmodel
AT brownpd therapeuticeffectofthematrixmetalloproteinaseinhibitorbatimastatinahumancolorectalcancerascitesmodel